Fovea Pharmaceuticals SA

Fovea Pharmaceuticals SA discovers and develops of drugs for the treatment of ocular diseases. It provides FOV1101/Prednisporin for the treatment of allergic conjunctivitis; FOV2302, a proprietary plasma kallikrein-kinin inhibitor for systemic treatment of hereditary angioedema; FOV2304 for the treatment of diabetic macular edema; and FOV2501, an intravitreal formulation of RdCVF designed to treat retinitis pigmentosa with extension to dry age related macular degeneration. The company was founded in 2005 and is based in Paris, France. As of October 30, 2009, Fovea Pharmaceuticals SA operates as a subsidiary of Sanofi.